Brain Injury Pipeline Review and Clinical Trials 2015 Market Insights and Research Reports

News provided by

Aug 26, 2015, 12:30 ET

PUNE, India, August 26, 2015 /PRNewswire/ --

Market research reports titled "Brain Injury - Pipeline Review, H2 2015" and "Brain Injury Global Clinical Trials Review, H1, 2015" are the latest brain injury publications now available under the pharmaceuticals section of RnRMarketResearch.com.

Complete H2 2015 report on brain injury pipeline review spread across 47 pages, talking about 6 major companies, as well as supported with 21 tables and 10 figures is now available at http://www.rnrmarketresearch.com/brain-injury-pipeline-review-h2-2015-market-report.html .

This report provides comprehensive information on the therapeutic development for Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies discussed in this brain injury pipeline review report for H2 2015 include Acorda Therapeutics, Inc., Biogen, Inc., Chiesi Farmaceutici SpA, Faron Pharmaceuticals Oy, FibroGen, Inc. and Virogenomics, Inc. Drug profiles covered include Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury, FG-4497, interferon beta-1a, Peptide to Inhibit Pannexin-1 for Brain Injury, PRE-084, Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury, Recombinant Protein to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury, RTL-551, Small Molecules to Block TRPC3 for Acute Brain Injury, Small Molecules to Inhibit Caspase-2 for Neonatal Brain Injury and Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury.

Global Markets Direct reports feature investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by an expert team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Order a copy of Brain Injury - Pipeline Review, H2 2015 market research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=411425 .

This latest market research on brain injury pipeline review provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. It helps identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage and develop strategic initiatives by understanding the focus areas of leading companies. Additionally, it is useful in identifying and understanding important and diverse types of therapeutics under development for Brain Injury. Easily, plan mergers and acquisitions effectively by identifying key players of the most promising pipeline, devise corrective measures for pipeline projects by understanding Brain Injury pipeline depth and focus of Indication therapeutics as well as develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope by reading this research. It also helps in modifying the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

The second market research report titled Brain Injury Global Clinical Trials Review, H1, 2015 provides top line data relating to the clinical trials on Brain Injury. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). These clinical trial reports are generated using a proprietary database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc. across the globe. Clinical trials database undergoes periodic update by dynamic process.

This research on clinical trials review of brain injury assists in formulating key business strategies with regards to investment and helps in identifying prominent locations for conducting clinical trials which saves time and cost. It provides top level analysis of global clinical trials market which helps in identifying key business opportunities, supports understanding of trials count and enrollment trends by country in global therapeutics market and aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials. The report also facilitates clinical trial assessment of the indication on a global, regional and country level.

Brain injury clinical trials overview of companies and institutes/organizations like Pfizer Inc., ZonMw, Novo A/S, Cato Research Ltd., Canbex Therapeutics Ltd., AstraZeneca Plc, Astellas Pharma Inc., AmKor Pharma, Inc., Alexander David Investments PLC (Inactive), Actavis Plc, Vanderbilt University, ALYN Pediatric and Adolescent Rehabilitation Center, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Shaanxi Provincial People's Hospital, Tabriz University of Medical Sciences, University of Nottingham, Assistance Publique - Hopitaux de Paris, Associacao de Assistencia a Crianca Deficiente, Atlantic Health System and Baycrest are covered in this research report spread across 87 pages and available at http://www.rnrmarketresearch.com/brain-injury-global-clinical-trials-review-h1-2015-market-report.html .

Explore more reports on therapeutics market as well as clinical trials industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/clinical-trial .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
[email protected]

Connect with Us:

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

SOURCE RnR Market Research